All Content

A new tool to add to your armamentarium?

What’s new in MS: teratogenicity of disease-modifying drugs, extended interval natalizumab dosing, a potential biomarker, the “MS hug,” and virtual reality therapy.

Around three times more women than men have migraine. This marked difference in prevalence is one of the most well-known features of the illness. Here's what history tells us.

A combination of biomarkers that might assist physicians in differentiating syncope from seizure; LiTT for intractable mesial temporal lobe epilepsy—these and other insights.

Autism diagnostic stability starts early, much MS misdiagnosis and unnecessary medication, CBD reduces seizures in children, and other recent findings are summarized here.

Patients with drug-resistant seizures should have an epilepsy center evaluation to confirm the diagnosis and determine the epilepsy syndrome and possible candidacy for neurosurgery. Guidelines here.

A patient with worsening atrial fibrillation experiences improvement of his symptoms and heart rate with chiropractic manipulation. More in this podcast.

Insights about where stem cell treatment of neurological diseases is headed.

These new studies describe events and risks that go after, or before, the onset of symptoms.

Patients with epilepsy often seek CAM therapies—with or without the recommendations or explicit approval of their neurologist.

How are you counseling patients and families about the risks and benefits of playing sports with repetitive head blows and the risk of CTE?

Advances in the diagnosis and management of SMA include molecular genetic testing and the FDA approval of a disease-modifying therapy.

Recent findings challenge previous assumptions about the genesis of atherosclerosis.

New guidelines reflect a growing interest in behavioral treatments and neuromodulation.